The majority are female (85%). The average age is 15±2.5 years. This cohort includes Hispanic (36%), Asian (29%), African-American (21%) and Caucasian (11%) children. LN class III or IV was diagnosed in 67% of patients. Nearly all were treated with hydroxychloroquine and steroids (95%). Other drugs used include mycophenolate mofetil (85%), cyclophosphamide (43%), rituximab (27%) and tacrolimus (2%). A significant increase in urinary HER2, TWEAK and VCAM1 levels was found in LN patients (p=0.005; p=0.006; p=0.01, respectively) when compared to controls. HER2 levels reflected disease activity, increasing during flares. In an adult cohort of LN patients (N=126) composed mainly of females (80%) with an average age of 46±13 years, we also found a significant increase of urinary HER2 when compared to controls (p=0.002). A strong correlation between the urinary levels of HER2, TWEAK and VCAM1 was not found. Conclusions: Urinary HER2, TWEAK and VCAM1 were significantly increased in a paediatric cohort of LN patients. In addition, significantly higher urinary HER2 levels were also found in an adult LN cohort. This on-going study will further evaluate if these urinary markers, alone or in combination, can reflect disease activity and predict renal flares, analysing their potential value in clinical practice. Background: Neuropsychiatric (NP) manifestations are a main cause of morbidity and mortality in juvenile-onset systemic lupus erythematosus (jSLE). Some studies suggest that they are more frequent and severe in jSLE than in adult-onset SLE (aSLE). Objectives: To compare the clinical and serological profile of pediatric and adult patients with neuropsychiatric lupus (NPSLE) treated in a Spanish tertiary center. Methods: A retrospective study of patients with jSLE (age of onset: 0-18y) and aSLE (age of onset: >18y) seen in our center during the period 1988-2016 was performed. Case definitions of the American College of Rheumatology were used to identify NPSLE manifestations. Demographics, clinical and serological data were obtained through a review of their medical records. Results: A total of 69 patients with NPSLE were included, aSLE 41 (59%) and jSLE 28 (41%), the comparison of groups is presented in the table. Most of them were Caucasian (92%), mean age at diagnosis in adults was 36.4 years (range: 19-68) and 13.9 years (range: 8-18) in children. The proportion of males was higher in the latter group. The mean duration of the disease was significantly greater in adults, as well as the time from SLE diagnosis to NP manifestation onset, although without significant difference. Central NP manifestations were the most frequent in both groups (aSLE 93%, jSLE 96%) regarding to the peripheral manifestations (aSLE 12%, jSLE 11%). The most frequent manifestations in aSLE were headache (29%), cerebrovascular disease (27%), seizures (17%) and myelopathy (15%), whereas in jSLE were seizures (46%), headache (29%), mood disorder/depression (25%), psychosis (18%) and autonomic disorders (18%). A significant group of patients presented ≥2 central manifestation during their evolution (aSLE 32%, jSLE 41%), with the mean number of manifestations in adults being 1.36 (range: 1-3) and in children 1.44 Range: 1-4). Patients with jSLE developed lupus nephritis (LN) with a significantly higher frequency, as well as higher titres of anti-DNA antibodies, erythrocyte sedimentation rate (ESR) and hypocomplementemia. During the study period there was mortality in 2 cases of aSLE and 2 jSLE (5% and 7%, respectively).
Thursday, 15 June 2017
Scientific Abstracts
The majority are female (85%). The average age is 15±2.5 years. This cohort includes Hispanic (36%), Asian (29%), African-American (21%) and Caucasian (11%) children. LN class III or IV was diagnosed in 67% of patients. Nearly all were treated with hydroxychloroquine and steroids (95%). Other drugs used include mycophenolate mofetil (85%), cyclophosphamide (43%), rituximab (27%) and tacrolimus (2%). A significant increase in urinary HER2, TWEAK and VCAM1 levels was found in LN patients (p=0.005; p=0.006; p=0.01, respectively) when compared to controls. HER2 levels reflected disease activity, increasing during flares.
In an adult cohort of LN patients (N=126) composed mainly of females (80%) with an average age of 46±13 years, we also found a significant increase of urinary HER2 when compared to controls (p=0.002).
A strong correlation between the urinary levels of HER2, TWEAK and VCAM1 was not found. Conclusions: Urinary HER2, TWEAK and VCAM1 were significantly increased in a paediatric cohort of LN patients. In addition, significantly higher urinary HER2 levels were also found in an adult LN cohort. This on-going study will further evaluate if these urinary markers, alone or in combination, can reflect disease activity and predict renal flares, analysing their potential value in clinical practice. 19-68) and 13.9 years (range: 8-18) in children. The proportion of males was higher in the latter group. The mean duration of the disease was significantly greater in adults, as well as the time from SLE diagnosis to NP manifestation onset, although without significant difference. Central NP manifestations were the most frequent in both groups (aSLE 93%, jSLE 96%) regarding to the peripheral manifestations (aSLE 12%, jSLE 11%). The most frequent manifestations in aSLE were headache (29%), cerebrovascular disease (27%), seizures (17%) and myelopathy (15%), whereas in jSLE were seizures (46%), headache (29%), mood disorder/depression (25%), psychosis (18%) and autonomic disorders (18%). A significant group of patients presented ≥2 central manifestation during their evolution (aSLE 32%, jSLE 41%), with the mean number of manifestations in adults being 1.36 (range: 1-3) and in children 1.44 Range: 1-4). Patients with jSLE developed lupus nephritis (LN) with a significantly higher frequency, as well as higher titres of anti-DNA antibodies, erythrocyte sedimentation rate (ESR) and hypocomplementemia. During the study period there was mortality in 2 cases of aSLE and 2 jSLE (5% and 7%, respectively). Background: Juvenile dermatomyositis (JDM) is a rare inflammatory myopathy seen in children. There have been few studies on long-term outcome in children with JDM Objectives: To assess long-term outcome of JDM using validated measures of outcome Methods: All children diagnosed to have JDM for more than 2 years and registered in Pediatric Rheumatology Clinic at PGIMER, Chandigarh, India, were deemed eligible for recruitment. Study period was from January 1, 2015 to June 30, 2016. Those who were not on regular follow-up were called for assessment which was done by a single observer using Childhood Myositis Assessment Scale (CMAS), Manual Muscle Testing 8 (MMT8), Myositis Disease Activity Assessment Tool (MDAAT), abbreviated cutaneous assessment tool (aCAT), Myositis Damage Index (MDI) and Childhood Health Assessment Questionnaire (CHAQ). Results: Thirty-five children were enrolled in this study, 22 (62.9%) were on regular follow-up. Mean age was 13.9yrs (range 4-29yrs). Mean age at diagnosis was 7.51yrs with median interval between onset of symptoms and diagnosis
